Jedd Wolchok

Jedd Wolchok led the pivotal CheckMate 067 phase III trial demonstrating superior survival with the combination of nivolumab plus ipilimumab compared to either agent alone in advanced melanoma, establishing combination checkpoint blockade as a cornerstone of cancer immunotherapy. His research characterized the durable long-term survival benefits of ipilimumab plus nivolumab with 6-year overall survival exceeding 49% in previously untreated advanced melanoma. He pioneered approaches to maximize the benefit of dual checkpoint blockade while managing immune-related adverse events through structured toxicity management protocols. His landmark clinical trial leadership fundamentally transformed the treatment and long-term outcomes for patients with advanced melanoma worldwide.